Resilient US Rebif, Gonal-f Q2 Sales Allow German Merck To Up Forecast

Solid US demand for Gonal-f fertility and Rebif MS drugs in the second quarter – along with commissions from its Xalkori co-promotion partnership there with Pfizer – let Merck KGaA upgrade its guidance for the full year.